Abstract: Provided are a pouch case and a secondary battery using the same. The pouch case includes a first receiving part and a second receiving part which are concavely formed; a sealing part formed along an outer portion of the pouch case so as to surround the first receiving part and the second receiving part; and a partitioning part formed between the first receiving part and the second receiving part and protruding from a bottom surface of each receiving part to partition the first receiving part and the second receiving part. As one side surface of the secondary battery in which an electrode assembly is received and packaged in the pouch case is formed in a plane form, a flat side surface is in close contact with a cooling plate, thereby maximizing cooling efficiency of the secondary battery.

Abstract: The present invention relates to a pharmaceutical composition, a health functional food, and a feed composition for the prevention, improvement, or treatment of non-alcoholic liver disease or insulin resistance comprising ginsenoside F2. The pharmaceutical composition according to the present invention comprising ginsenoside F2 can inhibit the adipogenesis and lipid accumulation in the liver, improve insulin sensitivity, inhibit the expression of inflammatory cytokines such as TNF-?, IL-?, and IL-6 in the Kupffer cell, inhibit the expression of endocannabinoid synthase, thus capable of effectively preventing or treating non-alcoholic liver disease or insulin resistance.

Abstract: The present invention relates to a method for improving drug metabolism function of human stem cell-derived hepatocytes. More precisely, the human stem cell-derived hepatocytes are similar in cell morphology to human hepatocytes but display reduced expressions of drug or alcohol metabolism associated enzymes and antioxidant enzymes. So, the inventors co-cultured the hepatocytes differentiated from human stem cells with mouse hepatic stellate cells. As a result, it was confirmed that alcohol mediated toxicity was reduced so that liver cell damage or apoptosis level was reduced. In the meantime, the expressions of drug and alcohol metabolism associated enzymes and antioxidant enzymes were increased.

Abstract: The present invention relates to a composition for preventing or treating liver cancer containing ginsenoside F2 as an active ingredient. Specifically, the composition according to the present invention kills liver cancer cells, specifically inhibits the formation of liver cancer, and reduces the expression of alanine aminotransferase (ALT) or aspartate aminotransferase (AST), without affecting normal hepatocytes, and thus can be usefully used as a therapeutic agent for liver cancer.

Abstract: The present invention relates to a composition for preventing or treating liver cancer containing ginsenoside F2 as an active ingredient. Specifically, the composition according to the present invention kills liver cancer cells, specifically inhibits the formation of liver cancer, and reduces the expression of alanine aminotransferase (ALT) or aspartate aminotransferase (AST), without affecting normal hepatocytes, and thus can be usefully used as a therapeutic agent for liver cancer.

Abstract: The present invention relates to a pharmaceutical composition, a health functional food, and a feed composition for the prevention, improvement, or treatment of non-alcoholic liver disease or insulin resistance comprising ginsenoside F2. The pharmaceutical composition according to the present invention comprising ginsenoside F2 can inhibit the adipogenesis and lipid accumulation in the liver, improve insulin sensitivity, inhibit the expression of inflammatory cytokines such as TNF-?, IL-?, and IL-6 in the Kupffer cell, inhibit the expression of endocannabinoid synthase, thus capable of effectively preventing or treating non-alcoholic liver disease or insulin resistance.

Abstract: Provided are use of ginsenoside F2 in the prevention, improvement or treatment of liver disease, and a pharmaceutical composition, a health functional food, and a feed composition including ginsenoside F2. Ginsenoside F2 inhibits fat synthesis and accumulation in the liver, and increases distribution of regulatory T cells capable of inhibiting activity of inflammatory cells, thereby preventing hepatitis, and also increases expression of anti-inflammatory cytokine IL-10 in regulatory T cells, and inhibits differentiation of naive T cells into Th17 cells, and is thereby effectively used for the treatment of various liver diseases.

Abstract: The present invention is related to a method of manufacture of an alkaline mineral bioactive solution of which raw materials are squid bones burnt at a high temperature and crushed powder of red seaweeds and to compositions and health foods having the efficacy for the prevention of osteoporosis. The alkaline aqueous solutions having abundant minerals of the present invention may be used for bioactive solutions having the efficacy for the prevention and improvement of osseous diseases such as osteolysis and osteoporosis in mammals including human beings.

Abstract: The present invention relates to natural and functional bean-curd having good storage stability and comprising various nutrients contained in Japanese apricots and red algae as well as those of soybean, which is—prepared by using fruit vinegar and red algae as natural coagulant. In the present invention, red algae and fruit vinegar employed as coagulant serves day as inorganic salts and as organic acid, respectively, to coagulate bean-curd, so that two coagulation principles work together, and thus it is distinguishable from conventional process for preparing bean-curd.

Abstract: The present invention is related to a method of manufacture of an alkaline mineral bioactive solution of which raw materials are squid bones burnt at a high temperature and crushed powder of red seaweeds and to compositions and health foods having the efficacy for the prevention of osteoporosis. The alkaline aqueous solutions having abundant minerals of the present invention may be used for bioactive solutions having the efficacy for the prevention and improvement of osseous diseases such as osteolysis and osteoporosis in mammals including human beings.

Abstract: Disclosed is a method for controlling a heat treatment in the process of fabricating a high purity silica glass via a sol-gel process using a low temperature heater having an inhalation line and an exhaust line. Accordingly, the method includes the steps of (a) identifying whether or not the diameter of the exhaust line is varied; (b) controlling the mass flow of the process gas according to the changed diameter of the exhaust line in step (a); (c) measuring an exhaust gas velocity discharged through the exhaust line; (d) comparing the exhaust gas velocity measured in the step (c) with the exhaust gas velocity after the scale of the exhaust line is varied; and, (e) repeating steps (b)-(d) if the comparison result in step (d) is different.

Abstract: The present invention discloses a method for fabricating silica glass using a sol-gel process, which includes a sol forming step for forming a sol by mixing a starting material, deionized water and an additive together; gelation step for gelatinizing the sol after filling a circular mold with the gel produced; gel drying step for separating the gel from the circular mold and drying the gel; setting step for placing the gel inside of a heat chamber and injecting helium gas into the heat chamber; and low heat treatment step for pressurizing and depressurizing an internal pressure of the heat chamber repeatedly for several times.

Abstract: A silica glass composition having silica and a binder is provided. The binder is methylcellulose or a polymer comprising repeating units represented by the formula (1): (—CH2—CH(OR)—)  (1) where R is a C1-C12 alkyl group or is the acetyl group. The silica glass composition according to the present invention includes a binder cheaper than the conventional polyethyloxazoline and is not hazardous to humans. The air bubbles removing efficiency can be enhanced by reducing the viscosity of the sol, and the content of solid in the sol can be increased by using the silica glass composition according to the present invention. Also, the strength of the wet gel is increased allowing the gel to be easily handled in a subsequent process. The silica glass composition according to the present invention can be used in manufacturing silica glass for a semiconductor device and an optical lens as well as a tube for optical fiber.

Abstract: A method for producing a dopant doped high pure silica glass comprising the steps of: preparing powder by dispersing silica particles into a dispersion medium; adding a dopant containing gas; drying, heating and pulverizing the same in sequence to produce dopant doped silica powder; and, producing a dopant doped silica glass by using the silica powder produced by said powder preparing step as a starting substance.

Abstract: Disclosed is a method for controlling a heat treatment in the process of fabricating a high purity silica glass via a sol-gel process using a low temperature heater having an inhalation line and an exhaust line. Accordingly, the method includes the steps of (a) identifying whether or not the diameter of the exhaust line is varied; (b) controlling the mass flow of the process gas according to the changed diameter of the exhaust line in step (a); (c) measuring an exhaust gas velocity discharged through the exhaust line; (d) comparing the exhaust gas velocity measured in the step (c) with the exhaust gas velocity after the scale of the exhaust line is varied; and, (e) repeating steps (b)-(d) if the comparison result in step (d) is different.